Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1
regimen in previously untreated metastatic RCC to select the most promising regimen, which
should be used in further studies of this patient population.